Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervic… Read more
Genmab A/S (GNMSF) - Net Assets
Latest net assets as of September 2025: $5.75 Billion USD
Based on the latest financial reports, Genmab A/S (GNMSF) has net assets worth $5.75 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.02 Billion) and total liabilities ($1.27 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.75 Billion |
| % of Total Assets | 81.91% |
| Annual Growth Rate | 16.01% |
| 5-Year Change | 91.92% |
| 10-Year Change | 952.48% |
| Growth Volatility | 54.26 |
Genmab A/S - Net Assets Trend (2002–2024)
This chart illustrates how Genmab A/S's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Genmab A/S (2002–2024)
The table below shows the annual net assets of Genmab A/S from 2002 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $36.70 Billion | +16.09% |
| 2023-12-31 | $31.61 Billion | +15.86% |
| 2022-12-31 | $27.28 Billion | +22.91% |
| 2021-12-31 | $22.20 Billion | +16.08% |
| 2020-12-31 | $19.12 Billion | +36.11% |
| 2019-12-31 | $14.05 Billion | +75.29% |
| 2018-12-31 | $8.01 Billion | +27.78% |
| 2017-12-31 | $6.27 Billion | +29.95% |
| 2016-12-31 | $4.83 Billion | +38.43% |
| 2015-12-31 | $3.49 Billion | +71.51% |
| 2014-12-31 | $2.03 Billion | +208.24% |
| 2013-12-31 | $659.52 Million | +72.12% |
| 2012-12-31 | $383.19 Million | -21.22% |
| 2011-12-31 | $486.42 Million | -54.96% |
| 2010-12-31 | $1.08 Billion | -16.74% |
| 2009-12-31 | $1.30 Billion | -40.73% |
| 2008-12-31 | $2.19 Billion | -24.09% |
| 2007-12-31 | $2.88 Billion | +79.36% |
| 2006-12-31 | $1.61 Billion | +43.69% |
| 2005-12-31 | $1.12 Billion | -5.27% |
| 2004-12-31 | $1.18 Billion | +8.70% |
| 2003-12-31 | $1.09 Billion | -22.35% |
| 2002-12-31 | $1.40 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Genmab A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2425327900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $23.55 Billion | 64.18% |
| Common Stock | $66.00 Million | 0.18% |
| Other Comprehensive Income | $490.00 Million | 1.34% |
| Other Components | $12.59 Billion | 34.31% |
| Total Equity | $36.70 Billion | 100.00% |
Genmab A/S Competitors by Market Cap
The table below lists competitors of Genmab A/S ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jack Henry & Associates Inc
NASDAQ:JKHY
|
$11.34 Billion |
|
UltraTech Cement Limited
PINK:UCLQF
|
$11.35 Billion |
|
Five Below Inc
NASDAQ:FIVE
|
$11.36 Billion |
|
Straumann Holding AG
PINK:SAUHF
|
$11.38 Billion |
|
AP Moeller - Maersk A/S A
PINK:AMKAF
|
$11.30 Billion |
|
XCMG Construction Machinery Co Ltd
SHE:000425
|
$11.30 Billion |
|
Companhia de Saneamento Básico do Estado de São Paulo - SABESP
F:SAJA
|
$11.28 Billion |
|
WEG S.A
SA:WEGE3
|
$11.28 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genmab A/S's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 31,610,000,000 to 36,697,000,000, a change of 5,087,000,000 (16.1%).
- Net income of 7,844,000,000 contributed positively to equity growth.
- Share repurchases of 3,879,000,000 reduced equity.
- Other comprehensive income increased equity by 430,000,000.
- Other factors increased equity by 692,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $7.84 Billion | +21.38% |
| Share Repurchases | $3.88 Billion | -10.57% |
| Other Comprehensive Income | $430.00 Million | +1.17% |
| Other Changes | $692.00 Million | +1.89% |
| Total Change | $- | 16.09% |
Book Value vs Market Value Analysis
This analysis compares Genmab A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.33x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.97x to 0.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $62.64 | $186.15 | x |
| 2003-12-31 | $47.59 | $186.15 | x |
| 2004-12-31 | $44.62 | $186.15 | x |
| 2005-12-31 | $35.79 | $186.15 | x |
| 2006-12-31 | $41.30 | $186.15 | x |
| 2007-12-31 | $65.61 | $186.15 | x |
| 2008-12-31 | $49.02 | $186.15 | x |
| 2009-12-31 | $28.89 | $186.15 | x |
| 2010-12-31 | $24.05 | $186.15 | x |
| 2011-12-31 | $10.83 | $186.15 | x |
| 2012-12-31 | $8.32 | $186.15 | x |
| 2013-12-31 | $12.71 | $186.15 | x |
| 2014-12-31 | $35.51 | $186.15 | x |
| 2015-12-31 | $57.37 | $186.15 | x |
| 2016-12-31 | $78.14 | $186.15 | x |
| 2017-12-31 | $101.01 | $186.15 | x |
| 2018-12-31 | $129.17 | $186.15 | x |
| 2019-12-31 | $220.75 | $186.15 | x |
| 2020-12-31 | $290.21 | $186.15 | x |
| 2021-12-31 | $336.07 | $186.15 | x |
| 2022-12-31 | $413.30 | $186.15 | x |
| 2023-12-31 | $479.56 | $186.15 | x |
| 2024-12-31 | $567.77 | $186.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genmab A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 21.38%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 36.44%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 1.25x
- Recent ROE (21.38%) is above the historical average (-9.64%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 34.21% | 0.00% | 0.00x | 1.13x | $338.76 Million |
| 2003 | -30.11% | -478.75% | 0.06x | 1.09x | $-435.76 Million |
| 2004 | 31.56% | 9087.83% | 0.00x | 1.08x | $254.59 Million |
| 2005 | -38.37% | -435.79% | 0.07x | 1.22x | $-541.15 Million |
| 2006 | -27.26% | -323.31% | 0.08x | 1.12x | $-598.99 Million |
| 2007 | -13.30% | -72.40% | 0.13x | 1.37x | $-671.70 Million |
| 2008 | -44.10% | -129.52% | 0.23x | 1.49x | $-1.18 Billion |
| 2009 | -77.92% | -172.46% | 0.26x | 1.71x | $-1.14 Billion |
| 2010 | -29.76% | -55.23% | 0.23x | 2.30x | $-429.46 Million |
| 2011 | -122.60% | -169.94% | 0.22x | 3.22x | $-645.01 Million |
| 2012 | -127.12% | -100.51% | 0.29x | 4.42x | $-525.44 Million |
| 2013 | 17.04% | 16.93% | 0.38x | 2.63x | $46.41 Million |
| 2014 | 14.82% | 35.43% | 0.30x | 1.41x | $98.00 Million |
| 2015 | 21.90% | 67.39% | 0.29x | 1.12x | $414.84 Million |
| 2016 | 24.59% | 65.36% | 0.35x | 1.09x | $704.41 Million |
| 2017 | 17.59% | 46.65% | 0.36x | 1.05x | $476.33 Million |
| 2018 | 18.37% | 48.66% | 0.36x | 1.06x | $670.71 Million |
| 2019 | 15.42% | 40.37% | 0.35x | 1.08x | $761.20 Million |
| 2020 | 24.88% | 47.06% | 0.48x | 1.11x | $2.85 Billion |
| 2021 | 13.32% | 34.86% | 0.34x | 1.11x | $737.40 Million |
| 2022 | 19.98% | 37.36% | 0.48x | 1.10x | $2.72 Billion |
| 2023 | 13.77% | 26.42% | 0.47x | 1.12x | $1.19 Billion |
| 2024 | 21.38% | 36.44% | 0.47x | 1.25x | $4.17 Billion |
Industry Comparison
This section compares Genmab A/S's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genmab A/S (GNMSF) | $5.75 Billion | 34.21% | 0.22x | $11.33 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |